Home › Employers › Neogene Therapeutics, Inc.
Neogene Therapeutics, Inc.: H-1B salaries and sponsorship
Neogene Therapeutics, Inc. filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $167,000.
Does Neogene Therapeutics, Inc. sponsor H-1B visas?
Neogene Therapeutics, Inc. filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Oct 29, 2024. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Sr. Manager, Sourcing and Procurement | 1 | $167,000 |
| Sr. Manager, Supply Chain | 1 | $155,000 |
| Sr. Manager Sourcing & Procurement | 1 | $179,130 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2023 | 2 | $161,000 |
| FY2025 | 1 | $179,130 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Sr. Manager Sourcing & Procurement | $179,130–$195,000 Level IV | Santa Monica, CA | Oct 29, 2024 | Dec 25, 2024 | Certified |
| Sr. Manager, Supply Chain | $155,000–$165,000 Level IV | Santa Monica, CA | Jul 20, 2023 | Jul 26, 2023 | Certified |
| Sr. Manager, Sourcing and Procurement | $167,000–$177,000 Level IV | Santa Monica, CA | Mar 30, 2023 | Apr 17, 2023 | Certified |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).